Frazier Lifesciences Acquisition Corporation announced the pricing of its upsized $120 million IPO this morning and its units are expected to begin trading on the Nasdaq under the symbol “FLACU” today, Wednesday, December 9.
The new company aims to combine with a biotechnology business with preclinical therapeutics that can meet development milestones with minimal additional investment. Frazier Lifesciences is led by CEO and Chairman James N. Topper alongside CFO and Director David Topper, VP and General Counsel Gordon Empey and VP of Acquisitions Max M. Nowicki.
Total SPAC deal count for 2020 year-to-date is now 218 with $74.2 billion in gross proceeds raised. This offering is expected to close on Friday, December 11.
Credit Suisse Securities (USA) LLC is acting as the sole book-running manager of the offering. Goodwin Procter LLP is serving as Issuer’s Counsel with Kirkland & Ellis LLP serving as Underwriter’s Counsel. WithumSmith+Brown, PC serves as auditor. Continental Stock Transfer & Trust Company LLC is acting as trustee.